Background/Objectives: Pentraxin 3 (PTX3), a member of the pentraxin superfamily, plays diverse roles in immunity and inflammation. Its dual role in tumorigenesis, exhibiting both protumoral and antitumoral effects, has been the subject of conflicting reports. High PTX3 expression levels in serum and tumor tissues have been associated with poor prognosis in various malignancies, suggesting its potential as a prognostic biomarker. Through this meta-analysis, we aim to comprehensively assess the prognostic significance of PTX3 protein expression in human malignancies and evaluate its potential as a pan-cancer prognostic marker. Methods: A systematic literature search was conducted across the PubMed, Embase, Web of Science, MEDLINE, and Cochrane Library databases. Studies were included if they assessed the association between PTX3 protein expression and overall survival (OS) in cancer patients. Hazard ratios (HRs) were pooled using a random-effects model. Subgroup analyses were performed based on the method of PTX3 assessment, and publication bias was evaluated using Egger’s and Begg’s tests. Results: Nine studies encompassing 1215 patients were included in the analysis. High PTX3 expression was significantly associated with poorer OS (HR = 1.89, 95% CI = 1.55–2.32,p< 0.01) with no significant heterogeneity (I2= 0%). Subgroup analysis revealed consistent results across different assessment methods (immunohistochemistry: HR = 1.93,p< 0.01; immunoassay: HR = 1.86,p< 0.01). However, publication bias was detected (Egger’s test,p= 0.03). Conclusions: High PTX3 protein expression is associated with a poor prognosis in various malignancies, supporting its potential as a prognostic biomarker.
背景/目的：正五聚蛋白3（PTX3）作为正五聚蛋白超家族成员，在免疫与炎症过程中发挥多种作用。其在肿瘤发生中的双重角色——既表现出促肿瘤效应又具有抗肿瘤作用——一直是争议性报道的主题。血清及肿瘤组织中PTX3高表达水平与多种恶性肿瘤不良预后相关，提示其作为预后生物标志物的潜力。通过本次荟萃分析，我们旨在全面评估PTX3蛋白表达在人类恶性肿瘤中的预后意义，并探讨其作为泛癌预后标志物的可能性。方法：系统检索PubMed、Embase、Web of Science、MEDLINE及Cochrane Library数据库。纳入标准为评估PTX3蛋白表达与癌症患者总生存期（OS）相关性的研究。采用随机效应模型合并风险比（HR）。根据PTX3检测方法进行亚组分析，并运用Egger检验和Begg检验评估发表偏倚。结果：共纳入9项研究，涵盖1215例患者。PTX3高表达与较差的OS显著相关（HR=1.89，95% CI=1.55–2.32，p<0.01），且无异质性（I²=0%）。亚组分析显示不同检测方法结果一致（免疫组化法：HR=1.93，p<0.01；免疫测定法：HR=1.86，p<0.01）。但检测到发表偏倚（Egger检验p=0.03）。结论：PTX3蛋白高表达与多种恶性肿瘤不良预后相关，支持其作为预后生物标志物的潜在价值。
肿瘤(癌症)患者之家